Relmada Therapeutics, Inc.

NasdaqGS:RLMD Stock Report

Market Cap: US$138.5m

Relmada Therapeutics Valuation

Is RLMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RLMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RLMD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RLMD's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for RLMD?

Other financial metrics that can be useful for relative valuation.

RLMD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does RLMD's PB Ratio compare to its peers?

The above table shows the PB ratio for RLMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.1x
MDWD MediWound
4.4x48.1%US$139.8m
ELTP Elite Pharmaceuticals
3.4xn/aUS$155.7m
CBST.F Cannabist Company Holdings
2.4x96.2%US$162.5m
RANI Rani Therapeutics Holdings
6.1x7.8%US$155.6m
RLMD Relmada Therapeutics
1.6x3.0%US$138.5m

Price-To-Book vs Peers: RLMD is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (4.1x).


Price to Earnings Ratio vs Industry

How does RLMD's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.5%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.5%
n/an/an/a
No more companies

Price-To-Book vs Industry: RLMD is good value based on its Price-To-Book Ratio (1.6x) compared to the US Pharmaceuticals industry average (1.7x).


Price to Book Ratio vs Fair Ratio

What is RLMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RLMD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RLMD's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RLMD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.59
US$10.88
+136.9%
78.5%US$25.00US$3.00n/a4
Mar ’25US$6.80
US$10.38
+52.6%
85.6%US$25.00US$3.00n/a4
Feb ’25US$4.56
US$10.38
+127.5%
85.6%US$25.00US$3.00n/a4
Jan ’25US$4.14
US$10.38
+150.6%
85.6%US$25.00US$3.00n/a4
Dec ’24US$2.51
US$10.38
+313.3%
85.6%US$25.00US$3.00n/a4
Nov ’24US$2.98
US$10.38
+248.2%
85.6%US$25.00US$3.00n/a4
Oct ’24US$3.00
US$10.38
+245.8%
85.6%US$25.00US$3.00n/a4
Sep ’24US$3.79
US$10.31
+172.1%
86.6%US$25.00US$3.00n/a4
Aug ’24US$2.56
US$10.63
+315.0%
87.5%US$26.00US$3.00n/a4
Jul ’24US$2.46
US$10.63
+331.9%
87.5%US$26.00US$3.00n/a4
Jun ’24US$2.72
US$10.63
+290.6%
87.5%US$26.00US$3.00n/a4
May ’24US$2.72
US$11.38
+318.2%
77.4%US$26.00US$3.00n/a4
Apr ’24US$2.26
US$11.38
+403.3%
77.4%US$26.00US$3.00n/a4
Mar ’24US$3.36
US$13.38
+298.1%
90.9%US$34.00US$3.00US$6.804
Feb ’24US$4.30
US$13.38
+211.0%
90.9%US$34.00US$3.00US$4.564
Jan ’24US$3.49
US$21.38
+512.5%
79.1%US$42.00US$3.00US$4.144
Dec ’23US$4.60
US$17.42
+278.6%
84.7%US$42.00US$6.50US$2.516
Nov ’23US$6.51
US$20.83
+220.0%
86.2%US$50.00US$7.00US$2.986
Oct ’23US$37.02
US$66.00
+78.3%
24.0%US$90.00US$42.00US$3.007
Sep ’23US$29.99
US$60.00
+100.1%
26.6%US$90.00US$42.00US$3.797
Aug ’23US$24.66
US$59.71
+142.2%
27.1%US$90.00US$42.00US$2.567
Jul ’23US$18.30
US$59.71
+226.3%
27.1%US$90.00US$42.00US$2.467
Jun ’23US$18.04
US$59.71
+231.0%
27.1%US$90.00US$42.00US$2.727
May ’23US$25.11
US$62.14
+147.5%
26.4%US$90.00US$42.00US$2.727
Apr ’23US$29.40
US$62.14
+111.4%
26.4%US$90.00US$42.00US$2.267
Mar ’23US$20.24
US$64.71
+219.7%
24.5%US$90.00US$42.00US$3.367

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.